Study of ALN-SNCA for early Parkinson's disease
Part of Bones, joints & muscles, Brain & nervous system, Mental health clinical trials.
This trial tests a new experimental drug called ALN-SNCA, given as an injection into the spinal fluid, for people with early Parkinson's disease. The goal is to see if it is safe and well-tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Parkinson's disease within the last 4 years.
- You either are not taking any Parkinson's medication, or you have been on a stable dose of medication for at least 3 months.
- Your body mass index (BMI) is 35 or less.
- You do not have any other serious medical condition that could affect the study results (like heart, lung, liver, or kidney disease).
- You are able to have a lumbar puncture (spinal tap) and an MRI safely.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This study tests an experimental treatment (LY3962681) for people with early Parkinson's. It aims to see if the treatment is safe and can slow the disease. You must have a confirmed diagnosis, be in good overall health, and have stable medication use.
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
This trial tests an experimental drug called MT101-5 for people recently diagnosed with Parkinson's disease. It aims to see if the drug is safe and can help control symptoms.
This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.